CMPS:NASDAQ
Compass Pathways PLC
US$9.52
arrow_upward
+5.66%(+0.51) 1 天
US$9.25
arrow_downward
-2.84% (-0.27)today开盘前
休市： 5月4日, GMT-4 16:00:00 · USD
search
所有股票代码
1 天
5 天
1 个月
6 个月
年初至今
1 年
5 年
最大
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 CMPS 生成关键数据洞见…
开盘价
US$9.17
最高价
US$9.62
最低价
US$9.02
市值
一二.八四亿
平均成交量
四三八.五二万
成交量
七〇三.〇〇
52 周最高价
US$10.21
52 周最低价
US$2.25
每股收益
-US$3.08
Beta 版
二.三九
流通股数
一.三五亿
员工人数
一五六
新闻报道
来自全网
资料
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine.
Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus.
Compass Pathways has entered partnerships with several independent psychedelic academic scientists, including Jason Wallach, Hamilton Morris, and Adam Halberstadt among others, to develop novel psychedelic drugs for potential medical use. Wikipedia
Compass Pathways PLC简介